Effectiveness and safety of dabigatran on non-valvular atrial fibrillation patients during perioperative period of radiofrequency catheter ablation

doi:10.3760/cma.j.issn.1673-4777.2016.08.001

Abstract：Objective To investigate the effectiveness and safety of dabigatran on non-valvular atrial fibrillation(AF) patients during perioperative period of radiofrequency catheter ablation(RFCA).Methods Totally 292 patients with non-valvular AF who had RFCA from January 2013 to September 2014 were retrospectively analyzed and divided into 2 groups according to use of anticoagulants:dabigatran group (146 cases) and warfarin group(146 cases).All patients were treated with regular anticoagulant therapies for 3 months after RFCA.The effectiveness and safety of drugs were compared between groups.Results There was no death during hospitalization and follow-up period in both groups.In dabigatran group,ischemic stroke occurred in 1 case and severe hemorrhage occurred in 2 cases(1 case of cardiac tamponade,1 case of gastrointestinal hemorrhage).In warfarin group,severe hemorrhage occurred in 3 cases(1 case of cardiac tamponade,1 case of hemothorax,1 case of puncture site hematoma).The dabigatran group and warfarin group had 8 and 7 cases of minor bleeding respectively.Incidences of total bleeding,severe hemorrhage and minor bleeding had no significant difference between groups(all P ＜0.05).The incidence of gastrointestinal irritative symptom in dabigatran group was significantly higher than that in warfarin group [11.0％(16/146) vs 4.1％ (6/146),P =0.022].Conclusions Dabigatran used for anticoagulant therapy in non-valvular AF patients during RFCA is safe and effective.Dabigatran can be the replacement therapy of warfarin.